Moeller 2003.

Methods	Four‐week, prospective, randomised study.
Participants	In‐patients fulfilling DSM‐IV criteria for unipolar depression. Exclusion criteria: patients who were not physically healthy, needed further medication, had a history of endocrine disorders, were pregnant or were suffering from alcohol or drug abuse. Age range: 19‐67 in citalopram group; 16‐64 in reboxetine group.
Interventions	Citalopram: 19 participants. Reboxetine: 17 participants. Citalopram fixed dose: 40 mg/day. Reboxetine fixed dose: 8 mg/day. Only diazepam and zaleplon were allowed as additional medications.
Outcomes	Primary outcome: basal prolactin levels from baseline to endpoint. Secondary outcomes: mean change on Hamilton Depression Rating Scale (HDRS) and Montgomery and Asberg Rating Scale for Depression (MADRS) scores from baseline to endpoint.
Notes	Three days before tests started, patients were treated exclusively with diazepam (for agitation) and zaleplon (for insomnia) in order to wash out previous antidepressant medication.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were assigned randomly".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "patients were not blinded about medication".
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided
Selective reporting (reporting bias)	Unclear risk	No information provided
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.